Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6 by MacDonald, Bryan T. et al.
Dissecting Molecular Differences between Wnt
Coreceptors LRP5 and LRP6
Bryan T. MacDonald, Mikhail V. Semenov
¤a, He Huang
¤b,X iH e *
F. M. Kirby Neurobiology Center, Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
Low-density lipoprotein receptor-related proteins 5 and 6 (LRP5 and LRP6) serve as Wnt co-receptors for the canonical b-
catenin pathway. While LRP6 is essential for embryogenesis, both LRP5 and LRP6 play critical roles for skeletal remodeling,
osteoporosis pathogenesis and cancer formation, making LRP5 and LRP6 key therapeutic targets for cancer and disease
treatment. LRP5 and LRP6 each contain in the cytoplasmic domain five conserved PPPSPxS motifs that are pivotal for
signaling and serve collectively as phosphorylation-dependent docking sites for the scaffolding protein Axin. However
existing data suggest that LRP6 is more effective than LRP5 in transducing the Wnt signal. To understand the molecular
basis that accounts for the different signaling activity of LRP5 and LRP6, we generated a series of chimeric receptors via
swapping LRP5 and LRP6 cytoplasmic domains, LRP5C and LRP6C, and studied their Wnt signaling activity using
biochemical and functional assays. We demonstrate that LRP6C exhibits strong signaling activity while LRP5C is much less
active in cells. Recombinant LRP5C and LRP6C upon in vitro phosphorylation exhibit similar Axin-binding capability,
suggesting that LRP5 and LRP6 differ in vivo at a step prior to Axin-binding, likely at receiving phosphorylation. We
identified between the two most carboxyl PPPSPxS motifs an intervening ‘‘gap4’’ region that appears to account for much
of the difference between LRP5C and LRP6C, and showed that alterations in this region are sufficient to enhance LRP5
PPPSPxS phosphorylation and signaling to levels comparable to LRP6 in cells. In addition we provide evidence that binding
of phosphorylated LRP5 or LRP6 to Axin is likely direct and does not require the GSK3 kinase as a bridging intermediate as
has been proposed. Our studies therefore uncover a new and important molecular tuning mechanism for differential
regulation of LRP5 and LRP6 phosphorylation and signaling activity.
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Introduction
The Wnt/b-catenin signaling pathway is essential for embry-
onic development and adult tissue homeostasis, consequently
mutation of many of the components result in human birth
defects, cancer and other diseases [1,2]. In the absence of a Wnt
ligand, the transcriptional co-activator b-catenin is continuously
degraded in the cyptoplasm by a protein complex including the
scaffolding protein Axin, tumor suppressor APC (adenomatous
polyposis coli), GSK3 (glycogen synthase kinase 3) and CK1a
(casein kinase 1a) [3]. The Axin complex mediates CK1a and
GSK3 phosphorylation of b-catenin to provide a binding site for
the b-Trcp E3 ubiquitin ligase, resulting in b-catenin ubiquitina-
tion and subsequent degradation. This process is inhibited when a
Wnt ligand brings together two types of receptors: the Frizzled (Fz
or FZD) serpentine receptors and the low-density lipoprotein
receptor-related protein 5 or 6 (LRP5 or LRP6). The intracellular
regions of FZD and LRP5 or LRP6 recruit the cytoplasmic
proteins Dishevelled (DVL) and Axin, respectively [3]. Recruit-
ment of Axin to the membrane by the Fz- LRP5/6 complex
inhibits b-catenin phosphorylation and allows b-catenin levels to
accumulate, resulting in b-catenin entering the nucleus and
interacting with TCF/LEF (T cell factor/lymphoid enhancer
factor) transcription factors to activate Wnt target gene transcrip-
tion [4,5].
LRP5 and LRP6 are the two LRP type of Wnt receptors in the
human and mouse genome, and are both widely/ubiquitiously
expressed [6,7,8,9,10]. Human LRP5 (1615 a.a.) and LRP6 (1613
a.a.) are 70% identical by paralogous conservation, and have a
similar domain structure that consists of a large extracellular
domain containing four b-propeller plus EGF repeats essential for
binding to Wnt and other ligands/antagonists and three LDLR-A
repeats [11]. The cytoplasmic region of LRP5/6 contains five
highly conserved PPPSPxS motifs that serve as phosphorylation-
regulated Axin binding sites [12,13]. LRP5 has a central role in
human bone mass regulation. Loss of function mutations in LRP5
result in osteoporosis-pseudoglioma (OPPG) primarily character-
ized by low bone mass [14]. On the other hand LRP5 ‘‘gain of
function’’ missense mutations, which are clustered in the first b-
propeller, cause high bone mass (HBM) disease [15,16], likely as a
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antagonists DKK1 and Sclerostin/SOST [17,18]. Only one or
two disease-causing LRP6 missense mutations have been found so
far, including the one associated with coronary artery disease and
osteoporosis [19], reflecting the likelihood that a severe or
complete loss of function of LRP6 is incompatible with
embryogenesis. Mouse models of the LRP5 [8,20] and LRP6
[21] mutations recapitulate the human disorders. Lrp52/2 mice
and heterozygous Lrp6+/2 mice are viable and exhibit OPPG/
osteoporosis phenotypes demonstrating their overlapping func-
tions in at least some aspects of bone development/homeostasis
[22]. However Lrp62/2 phenotypes are much more severe, as
embryos resemble a composite phenotype of several canonical
Wnt loss of function mutations and typically die during late stages
of embryogenesis [7]. The severity of the Lrp62/2 phenotype is
made worse by removing one or both alleles of Lrp5 and the
resulting embryos die very early in development [23]. Indeed
Lrp5/6 double knockout mutants fail to undergo gastrulation and
closely resemble the phenotype of Wnt3 knockout mice [23,24].
Collectively these data demonstrate that LRP6 has a more
prominent role than LRP5 during development and that LRP5
and LRP6 together are essential for transducing Wnt/b-catenin
signaling.
Other studies have peripherally compared the relative activities
of LRP5 and LRP6. Expression of LRP6 alone, but not LRP5
alone, is able to induce a secondary axis in Xenopus embryos [25].
Similarly in mammalian cell culture, LRP5 only weakly activates
the Wnt pathway in the absence of an exogenous Wnt, in contrast
to the highly active LRP6 [25,26]. On the other hand,
coexpression of LRP5 and Wnt synergistically activates b-catenin
signaling in both Xenopus embryos and mammalian cells [27].
These results are consistent with genetic studies that LRP6 appears
to be the stronger of the two receptors in the Wnt pathway.
Given the importance of LRP5 and LRP6 in development and
human diseases, we chose to dissect the molecular basis that
distinguishes and regulates LRP5 and LRP6 functions by
generating a series of LRP5/6 chimeric proteins. Our results
suggest that despite highly conserved PPPSPxS motifs shared by
both receptors, LRP6 cytoplasmic domain (LRP6C) harbors
stronger signaling activity than that of LRP5 (LRP5C), likely
owing to the fact that PPPSPxS motifs are more readily
phosphorylated in LRP6 than in LRP5. We further identified
between the two most carboxyl PPPSPxS motifs an intervening
region that appears to account for most of the difference in
phosphorylation and signaling capacity between LRP5C and
LRP6C. Finally we show that LRP5/LRP6-binding to Axin is
likely direct without GSK3 acting as an intermediary physical
bridge.
Results
A predominant role of Lrp6 in Wnt signaling in MEFs
To compare the activity of the endogenous Lrp5 and Lrp6 we
derived mouse embryonic fibroblasts (MEFs) from the wild-type
(WT) +/+, Lrp52/2, and Lrp62/2 embryonic day 14 (E14)
embryos. We analyzed the expression of the endogenous receptors
and confirmed the absence of protein in our knockout cells
(Figure 1A). Furthermore we detected roughly half as much Lrp6
protein in MEFS derived from Lrp6+/2 heterozygotes. We found
that WT MEFs treated with Wnt3a conditioned media (CM)
displayed a strong increase in cytosolic b-catenin levels compared
to cells treated with the control CM (Figure 1B). Lrp52/2 MEFS,
which only express the endogenous Lrp6 protein, displayed a
slightly diminished response to Wnt3a compared to WT MEFs
(Figure 1B). However Lrp62/2 MEFs, which only express the
endogenous Lrp5 protein, exhibited a much weaker response to
Wnt3a CM. We found similar results when using Wnt1 CM in the
Lrp52/2 and Lrp62/2 knockout MEFS (data not shown).
Additionally the Lrp52/2; Lrp6+/2 MEFS, which contained
only one allele of Lrp6, displayed a higher Wnt response
compared to Lrp62/2 cells containing two alleles of Lrp5
(Figure 1B). With the caveat that we do not know the abundance
of Lrp5 or Lrp6 proteins on the cell surface, these results suggest
that a majority of Wnt/b-catenin signaling in MEFs is mediated
through Lrp6.
LRP6C exhibits stronger signaling activity than LRP5C
We set out to generate chimeric receptors between LRP5 and
LRP6 to dissect their functional differences (Figure 2A and Figure
S1A). In the process we found that the signal peptide of LRP5 is
less active than that of LRP6, as *LRP5, in which the signal
peptide of LRP6 replaced that of LRP5, exhibited a modest
increase in the total protein level compared to the WT LRP5
(Figure 2B and 2C). Expression of *LRP5, but not of LRP5,
showed a modest Wnt pathway activation in the Wnt responsive
TOPFLASH luciferase assay, although this activation remained
much weaker than that by expression of LRP6 alone (Figure 2D).
In the presence of Wnt1 co-expression, however, *LRP5 and
LRP5 exhibited virtually identical activity (Figure 2E). We
speculate that under our experimental conditions of LRP5 or
LRP5* over-expression, only a portion, but not all, of LRP5 or
*LRP5 is activated by Wnt1, possibly due to availability of specific
Fz proteins (and/or other factors such as LRP chaperones). For
comparison of the mature LRP5 and LRP6 proteins (i.e., after the
removal of the signal peptide) we made various LRP5/LRP6
chimeric proteins using *LRP5 and LRP6.
We first generated *LRP5/6C and LRP6/5C by swapping the
cytoplasmic domain between *LRP5 and LRP6 (Figure 2F).
Compared to *LRP5, *LRP5/6C displayed higher activity when
expressed alone or in the presence of Wnt1 (Figures 2G and 2H).
On the contrary LRP6/5C was much weaker and in fact was
mostly inactive alone or in synergy with Wnt1 (Figure 2G and 2H).
In repeating experiments LRP6/5C sometimes behaved as a
dominant negative receptor such that the co-expression of LRP6/
5C suppressed Wnt1-stimulated reporter activity. We noticed that
the difference of signaling activity by over-expressed *LRP5 versus
LRP6 in the absence of Wnt1 co-expression was drastic (about 8
folds, Figure 2G); in the presence of Wnt1 co-expression both
*LRP5 and LRP6 were significantly activated but the difference
between *LRP5 and LRP6 was quite smaller (about 2 folds,
Figure 2H). One possibility is that under over-expression condition
only a portion, but not all, of *LRP5 or LRP6 is activated by Wnt1
due to the availability of specific (and endogenous) Fz proteins. We
also note the caveat that signaling by over-expressed *LRP5 or
LRP6 alone may or may not be Fz-dependent.
To further map the activity difference between LRP5C and
LRP6C, we utilized a conserved PstI site located after PPPSPxS
motif B in both LRP5 and LRP6 to divide the cytoplasmic domain
into two parts, which contain motifs A plus B, and motifs C plus D
plus E, respectively (Figure 3A and Figure S1B). These series of
*LRP5 and LRP6 chimeric receptors were expressed at compa-
rable levels, respectively (Figure 3B, data not shown). *LRP5/6
AB
and *LRP5/6
CDE, like *LRP5/6C, displayed higher activity
compared to *LRP5 alone (Figure 3C). In the presence of Wnt1,
*LRP5/6
CDE was similar to the *LRP5/6C, and both showed
stronger activity than *LRP5/6
AB, which in turn was more active
than *LRP5 (Figure 3D). Reciprocally, we observed signaling
activities in the following rank order: LRP6.LRP6/5
AB (which
Comparison of LRP5 and LRP6
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CDE (which
contained the A and B motifs of LRP6).LRP6/5C (Figure 3C
and 3D). We found similar results when LRP5 replaced *LRP5 in
the generation of analogous chimeric receptors, and with either
Wnt1 or Wnt3a (Figure S2A and S2B, and data not shown). These
results together suggest that the first half (containing the A and B
motifs) and the second half (containing the C, D, and E motifs) of
LRP6 each confer more signaling activity than their LRP5
counterparts, and that the second half of LRP6C confers the
strongest signaling activity. These results are consistent with our
previous studies that LRP6 signaling is mostly mediated by C plus
D plus E motifs [28,29].
Comparison of Axin interaction with phosphorylated
LRP5 and LRP6
Axin recruitment to activated/phosphorylated LRP5 or LRP6
has been well documented [30,31,32] and is believed to be a key
step in Wnt signal transduction [3]. The significant difference
between the Wnt signaling activity of LRP5C and LRP6C is
surprising considering that the five PPPSPxS motifs, which are
phosphorylation-dependent Axin docking sites, are virtually iden-
tical pair-wise between LRP5 and LRP6 (Figure S1B). We
attempted to compare Axin binding to LRP6 and LRP6/5C,
which exhibited highest and lowest signaling activities, respectively,
via coimmunoprecipitation in cells. However as activated LRP6
signaling degrades the Axin protein as previously observed [33], we
found that LRP6 expression resulted in much lower Axin levels
compared to LRP6/5C expression (at both one and two days post-
transfection, data not shown). Since these unequal Axin levels
complicated the binding experiment, we chose to use a different in
vitro approach that examines binding between Axin and recombi-
nant LRP5CorLRP6C(fusedwithGST,glutathioneStransferase).
Previously we used this method to show that GST-LRP6C, upon
phosphorylation by GSK3 plus CK1 in vitro, binds to Axin [13].
We purified GST-LRP5C (last 207 a.a. of LRP5) and GST-LRP6C
(last 218 a.a. of LRP6), and subjected them to in vitro
phosphorylation with recombinant GSK3 plus CKI in the presence
(or absence) of ATP. Similar to phosphorylated GST-LRP6C [13],
phosphorylated GST-LRP5C exhibited a slower migration pattern
in gel electrophoresis (Figure 4A). Given the pair-wise conservation
between PPPSPxS motifs of LRP5 and LRP6, we used phospho-
specific antibodies that we have raised against motifs A, C, and E of
LRP6 to examine the relative amount of phosphorylation of GST-
LRP5C and GST-LRP6C. We detected similar intensities of
phosphorylation at these three motifs with Ab1490 for phospho-
motif A [12], Ab1572 for phospho-motif C [28], and Ab1607 for
phospho-motif E [28] (Figure 4B–D). These antibodies by large
werespecific for phosphorylation of both LRP5and LRP6 (Figure 4
B–D), although a minorexceptionwasAb1490, whichcross-reacted
slightly with unphosphorylated GST-LRP5C (Figure 4B). None-
theless these experiments showed relatively comparable levels of
phosphorylation of LRP5C and LRP6C by GSK3 and CK1 in
vitro. Importantly, we found that phosphorylated, but not unpho-
sphorylated, LRP5C and LRP6C each bound to the Axin protein
from cell lysates at apparently comparable levels (lanes 6 and 9,
Figure 4G). These data suggest that LRP5 and LRP6, if
phosphorylated similarly, exhibit similar abilities to bind/recruit
Axin.
Axin-LRP5/6 association is unlikely bridged by GSK3
How phosphorylated/activated LRP5 or LRP6 binds to Axin
remains somewhat debated. The initial finding that Axin binds to
LRP5C in the yeast two-hydrid assay implied that the interaction
might be direct [30], and phosphorylated PPPSPxS motifs in
LRP6C were subsequently shown to mediate Axin-docking
[12,13], supporting a LRP5/6-Axin direct binding model.
However since LRP6 can also bind to GSK3 [13,34], possibly
through PPPSP motifs that are substrates for GSK3 [13,35], and/
or through an upstream serine/threonine-rich region in LRP6
(Figure S1B) [36,37], an alternative model was proposed that
GSK3, which is known to complex with Axin, acts as a bridge
between LRP6 and Axin [36]. We therefore designed experiments
to test these two models for both LRP5 and LRP6. After
phosphorylation of GST-LRP5C and GST-LRP6C by GSK3 plus
CK1 we extensively washed these GST-fusion proteins on
glutathione beads using a high salt condition (Figure 4E).
Compared to input GSK3 and GSK3 reference standards,
GST-LRP5C and GST-LRP6C proteins post washing retained a
small amount of GSK3, which was independent of LRP5C/
LRP6C phosphorylation and was not found in the lane of GST
alone (Figure 4E), consistent with the direct and specific LRP6-
GSK3 binding as previously reported [13,34,35]. However these
LRP5/6-bound GSK3 proteins were not capable of recruitment of
Axin into the complex (lanes 5 and 8, Figure 4G). The serine/
threonine cluster upstream of PPPSPxS motifs was suggested to be
a GSK3-binding site that can mediate LRP6C-GSK3-Axin
interaction [36]. We generated a 14-amino acid deletion of this
S/T cluster, LRP6CDS/T (Figure S1B), which we found exhibited
phosphorylation-dependent Axin binding that was indistinguish-
able from LRP6C (Figure 4H). Our results therefore do not
support the model that GSK3 bridges LRP5/6-Axin association
and are consistent with a direct LRP5/6-Axin binding through
phopshorylated PPPSPxS motifs.
Figure 1. Lrp62/2 MEFs are less responsive than Lrp52/2 or WT MEFs to Wnt3a stimulation. (A) Endogenous expression of LRP5 and
LRP6 in the mutant MEFS from total cell lysates. b-tubulin was used as a loading control. (B) Accumulation of cytoplasmic b-catenin in response to
6 hours of treatment of control L cell conditioned media (L) or L-Wnt3a conditioned media (W3A)examined via immunoblotting. Densitometry of
cytosolic b-catenin levels, normalized to cytsolic b-tubulin loading control bands, are shown below each lane.
doi:10.1371/journal.pone.0023537.g001
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modulate LRP5/6 signaling activity
Our in vitro binding results suggested that when similarly
phosphorylated, LRP5 is as effective as LRP6 in binding to Axin,
consistent with the high conservation of the five PPPSPxS motifs
found in LRP5 and LRP6. However in the context of the full-
length receptor, LPR5C is much less effective in activating Wnt
signaling. One possible explanation is that LRP6 is more readily
phosphorylated than LRP5 in vivo, and the amino acid residues
outside the conserved PPPSPxS motifs may be responsible for the
observed functional difference. An alignment of LRP5C and
LRP6C from multiple vertebrate species reveals several gaps,
Figure 2. LRP5 and LRP6 cytoplasmic domains (LRP5C and LRP6C) show significant difference in signaling activities. (A) Schematic
representation of LRP5/LRP6. SP: signal peptide; 1–4, propeller plus EGF-repeat 1 to 4; LDLRA: LDL receptor type A repeats; TM: transmembrane
domain; A–E: PPPSPxS motifs A to E. BspEI was introduced together with the VSVG tag after the SP (Figure S1A); ClaI was introduced immediately after
the TM domain and the endogenous PstI is immediately after the motif B (Figure S1B). These restriction sites were used to generate chimeric
receptors. (B) Schematic LRP5 (blue) and LRP6 (red) used for the signal peptide exchange experiment. (C) LRP5, *LRP5, and LRP6 levels in lysates from
HEK293T cells that were transfected with the respective expression plasmid, as detected by a VSVG antibody. (D and E) TOPFLASH reporter activity of
LRP5, *LRP5, and LRP6 alone (D) or co-expressed with Wnt1 (E) in HEK 293T cells. Wnt responsive TOPFLASH (firefly) luciferase units were internally
controlled to the non-Wnt responsive Renilla reporter, and were normalized to vector control and presented as relative luciferase units (RLU). The
dotted green line in E represents the activity of Wnt1 alone (through the endogenous receptor). (F) Schematic LRP5 (blue) and LRP6 (red) used for
cytoplasmic domain swap experiments. (G and H) TOPFLASH reporter activity of chimeric LRP5/6 receptors expressed alone (G) or co-expressed with
Wnt1 (H).
doi:10.1371/journal.pone.0023537.g002
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amino acid residues between PPPSPxS motifs (Figure S1B). We
first introduced these gap amino acid residues into LRP6/5C,
which behaved inactive or slightly dominant negative. Addition of
Gap1, Gap 2 or Gap3 did not significantly alter the activity of
LRP6/5C (Figure 5A). To our surprise, the addition of the gap4
serine residue between motifs D and E in the LRP6/5C+gap4
mutant resulted in high signaling activity that was comparable to
LRP6 (Figure 5A). LRP6/5C+gap4 also resembled LRP6 when
co-expressed with Wnt1, while LRP6/5C or each of LRP6/
5C+gap1/2/3 derivatives behaved inactive (in fact dominant
negative) (Figure 5B). Importantly, we detected phosphorylation at
motifs A, C, and E in LRP6 and LRP6/5C+gap4, but not in
LRP6/5C or LRP6/5C+gap1/2/3 (Figure 5C). These data are
consistent with the idea that LRP5C is less active in vivo due to
poorer phosphorylation, and demonstrate that introduction of
gap4 is sufficient, at least in part, to enhance LRP5 phosphory-
lation and signaling. We next introduced these gaps in the full
length *LRP5. *LRP5+gap4, but none of the *LRP5+gap1/2/3
derivatives, resulted in elevated signaling activity with Wnt1 to a
level comparable to that of LRP6 (Figure 5D).
The serine residue in the gap4 region was intriguing and hinted
the possibility of regulation via post-translational modifications
such as phosphorylation. However this seemed unlikely as an
alanine insertion in the place of the serine residue still conferred
significant signaling enhancement in the *LRP5+gap4A mutant
(Figure 6D). Further inspection of the gap4 region in LRP5, SYF,
versus SYSH in LRP6 (Figure 6A and 6B), prompted us to
generate *LRP5F.H, in which the phenylalanine (LRP5 residue
1601) was replaced by histidine. *LRP5F.H also exhibited
significant higher activity than *LRP5 (Figure 6D). We thus
considered the scenario that the tyrosine residue and its possible
phosphorylation in gap4 may be differentially regulated in LRP5
versus LRP6 due to the neighboring F versus H change (Figure 6A,
6B and Figure S1B). But this also seemed unlikely because
replacement of the tyrosine by phenylalanine had little effect on
signaling by either *LRP5 or LRP6 (data not shown). These results
suggest that the collective context of gap4 residues plays a major
role in the activity difference between LRP5 and LRP6.
We generated reciprocal changes in LRP6. Removing gap1 or 2
or 3 in LRP6 did not affect its signaling function (data not shown),
mirroring the little effect of insertion of these gaps each in LRP5
(Figure 5A and 5B). Similar to the *LRP5 data that the serine
residue per se in gap4 is not essential, a deletion of serine 1598 or
its replacement by alanine in LRP6DS1598 and LRP6S1598A,
respectively, did not affect LRP6 signaling (Figure 6E and 6F).
Importantly however, a substitution of serine 1598 and histidine
1599 in LRP6 gap4 with phenylalanine, generating the
LRP6SH.F mutant that had a gap4 resembling that in LRP5,
significantly diminished LRP6 signaling activity (Figure 6E and
6F). Note that the reduction of activity in LRP6SH.F was on par
to that observed in the LRP6e mutant, which has a non-functional
PPPAP alteration in motif E, and was much more pronounced
than that observed in LRP6a or LRP6b mutants harboring a non-
functional PPPAP alteration in motif A and B, respectively
(Figure 6E and 6F) [28]. Thus the gap4 contribution to LRP6
signaling is similar to that by PPPSPxS motif E but more
significant than that by motif A or B. These reciprocal data in
LRP5 and LRP6 demonstrate that the gap4 region between the
last two PPPSPxS motifs (D and E) accounts for most of the
Figure 3. Additional analyses of the cytoplasmic domain of LRP5 and LRP6. (A) Schematic LRP5 (blue) and LRP6 (red) receptors used for the
cytoplasmic domain swap experiment. (B) Chimeric LRP5/6 protein levels in lysates from HEK293T cells transfected with the respective expression
plasmid, as detected by a VSVG antibody. (C and D) TOPFLASH reporter activity of chimeric LRP5/6 transfected alone (C) or co-transfected with Wnt1
(D).
doi:10.1371/journal.pone.0023537.g003
Comparison of LRP5 and LRP6
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23537Figure 4. Phosphorylated LRP5 and LRP6 cytoplamic domain bind similarly and directly to Axin in vitro. (A–D) Purified GST-LRP5C and
GST-LRP6C were phosphorylated in vitro at 30uC for 4 hours in the presence of recombinant GSK3 and CKI plus ATP. Total protein staining
(SimplyBlue) (A) shows that phosphorylated LRP5C and LRP6C exhibit slower and smeary migration, as we previously reported for LRP6C [13].
Phosphorylation of LRP5C and LRP6C at motif A was detected via Ab1490 (B), at motif C via Ab1572 (C), and at motif E via Ab1607 (D). (E)
Recombinant GSK3 can associate with LRP5C and LRP6C (but not GST) regardless of their phosphorylation status. GSK3 used to phosphorylate LRP5C
and LRP6C was mostly washed away via high salt buffer prior to the in vitro Axin binding experiments. Top: GSK3 in the in vitro reaction prior to
wash; middle: GSK3 post wash; bottom: LRP5C and LRP6C phosphorylation at motif E; right: two exposures of the same serial dilutions of GSK3 to
show the relative amount of GSK3 bound to GST-LRP5C and GST-LRP6C. (F) Protein levels after the Axin binding experiment in (G), showing
comparable amounts of GST, GST-LRP5C, and GST-LRP6C in different lanes. The protein bands around the GST size in lanes 4 to 9 likely represent
partial proteolytic products. (G) Axin binds equivalently and specifically to phosphorylated LRP5C and LRP6C. Remaining recombinant GSK3 bound to
LRP5C and LRP6C in the in vitro reaction is also shown. Immunoblotting was done with both anti-Myc (for Myc-tagged Axin) and anti-GSK3
antibodies. Note that Axin did not bind to unphosphorylated GST-LRP5C or –LRP6C even in the presence of LRP5/6C-bound GSK3. (H) Deletion of the
entire serine/threonine-rich region in GST-LRP6CDS/T (a 14-amino acid residue deletion, Figure S1B) had minimal effects on Axin binding to
phosphorylated LRP6C.
doi:10.1371/journal.pone.0023537.g004
Comparison of LRP5 and LRP6
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Wnt receptors.
Discussion
The LRP5 and LRP6 genes likely arose from duplication of a
single ancestral gene approximately 500 million years ago during
the emergence of the chordate phylum. Since then LRP5 and
LRP6 have retained a relatively high degree structural similarity
and paralogous conservation, resulting in partially redundant
functions as Wnt receptors in vertebrates. However since this early
gene duplication, it is likely that LRP5 and LRP6 have
independently evolved to the receptors they are today in the
human genome. Genetic studies suggest that LRP6 has a more
dominant role in Wnt signal transduction [3]. Consistent with the
severity of the developmental phenotypes of Lrp5 and Lrp6
mutant mice [22,23], our comparison of the MEFs deficient for
Lrp5 or Lrp6 indicates that a majority of Wnt/b-catenin signaling
is mediated through Lrp6 (Figure 1). Moreover we were able to
show a dose dependent correlation of Wnt responsiveness in
MEFS containing two, one or no functioning Lrp6 alleles. Our
data in MEFs in general are consistent with the previous genetic
analyses of Lrp5 and Lrp6 compound mutant mice with different
allelic combinations [22,23]. Further evidence of the critical
importance of LRP6 is found through interspecies protein
comparisons. The orthologous conservation of human LRP6 to
mouse (98%), chicken (92%) and Xenopus (85%) Lrp6 is greater
than human LRP5 to mouse (94%), chicken (88%) and Xenopus
(80%) Lrp5 (Percentage numbers represent amino acid sequence
identity based on BLAST2 comparisons, data not shown),
indicating that LRP6 is more conserved during evolution whereas
changes in LRP5 may be more tolerable to the organism. These
observations may also in part explain the small number of
identified human LRP6 mutations in the literature compared to
those of LRP5 [19,38]. In this study we aimed to understand the
molecular underpinning that accounts for different LRP5 and
LRP6 signaling activities for two considerations. First, both LRP5
and LRP6 are key therapeutic targets for treatment of human
diseases including cancer and/or osteoporosis; and secondly,
LRP5 and LRP6 share five virtually identical orthologous
PPPSPxS motifs, implying that other unknown mechanisms may
operate to tune the Wnt receptor activities through these motifs.
By generating a series of reciprocal chimeric receptors between
LRP5 and LRP6, we found that difference between the
cytoplasmic domain of LRP5 and LRP6 underlies, to a significant
degree, the different signaling activities of these two receptors
(Figure 2). Our previous comprehensive analysis has revealed that
the five PPPSPxS motifs, from A to E (Figure S1B), contribute to
LRP6 signaling in the rank order of C.D=E.A.B, with the
carboxyl C, D, and E cluster making up most of the LRP6
signaling output [28]. Comparing LRP5 and LRP6, we found that
motifs A plus B in LRP6 have stronger activity than the
corresponding A and B pair in LRP5, while similarly the cluster
of motifs C and D and E of LRP6 is more potent than that of
LRP5 (Figure 3 and Figure S2). Most strikingly, our analysis
identified between motifs D and E a short intervening region,
termed gap4, which has significant and reciprocal effects on LRP5
and LRP6 activities. Thus LRP5 with an altered and ‘‘LRP6-like’’
Figure 5. The gap4 region between the most carboxyl terminal PPPSPxS motifs regulates LRP5 activity and PPPSPxS
phosphorylation. (A and B) TOPFLASH reporter activity of LRP6, LRP6/5C and its gap1–4 insertional derivatives transfected alone (A) or co-
transfected with Wnt1 (B). (C) PPPSPxS phosphorylation at motifs A, C, and E of LRP6, LRP6/5C and its gap1–4 insertional derivatives, as detected via
phosphorylation-specific antibodies. Receptor protein levels were detected via the VSVG antibody. The 220 kDa molecular weight marker is visible in
the first lane. (D) TOPFLASH reporter activity of *LRP5 and its gap1–4 insertional derivatives that were co-transfected with Wnt1.
doi:10.1371/journal.pone.0023537.g005
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LRP6 with an altered and ‘‘LRP5-like’’ gap4 region exhibits
weaker signaling similar to LRP5 (Figures 5 and 6). Indeed our
data suggest that the contribution by gap4 to LRP6 signaling is on
par to that by motif E and is more prominent than that by motif A
or B (Figure 6) [28,29].
It has been established that Axin binds to both LRP5 [30] and
LRP6 [32], and that phosphorylated PPPSPxS motifs provide
Axin-docking sites that mediate LRP6 signaling [12]. The
difference between LRP5 and LRP6 signaling could therefore be
a result of their different Axin-binding properties. But we found
that recombinant LRP5C and LRP6C, upon in vitro phosphor-
ylation by GSK3 and CK1, exhibit indistinguishable phosphor-
ylation-dependent binding to Axin (Figure 4), suggesting that the
difference of LRP5 and LRP6 signaling in vivo is likely at a step
prior to Axin-binding, i.e., at how effectively the PPPSPxS motifs
are phosphorylated. Fully consistent with this possibility, we found
that, using antibodies specific for phospho-A, -C, and –E, LRP6 is
more readily phosphorylated at these PPPSPxS motifs than its
LRP5 counterparts (Figure 5). More revealingly, the gap4 region
in LRP5 when altered to resemble that in LRP6 not only enhances
LRP5 signaling but also LRP5 phosphorylation at these PPPSPxS
motifs (Figure 5C). On the other hand other gap regions (gaps1, 2,
and 3) have minimal effects on LRP5 signaling or phosphorylation
(Figure 5). Thus we suggest that the difference in LRP5 and LRP6
signaling activity is largely due to their effectiveness of phosphor-
ylation at PPPSPxS motifs, and we have identified the gap4 region
that is responsible, at least in a significant part, for the difference
between LRP5 and LRP6 phosphorylation and signaling.
The gap4 region lies between motifs D and E, but it has a strong
effect on phosphorylation of not only motif E (and possibly D), but
also of motifs C and A that are some distance away (Figure 5C and
Figure S1B). We believe that this is consistent with the ‘‘LRP6
signal amplification’’ model we previously proposed [28], which
corroborates genetic observations in Drosophila embryos [39]. This
model is based on the observation of a local positive feed forward
loop between Axin and LRP6 PPPSPxS motifs. Thus Axin not
only binds to phosphorylated PPPSPxS motifs, but also promotes
and is required for PPPSPxS phosphorylation via its recruitment of
the Axin-GSK3 complex [28,40]. Therefore phosphorylation of
one PPPSPxS motif has a stimulatory effect on that of other
PPPSPxS motifs. Indeed we previously demonstrated that LRP6
phosphorylation at C or E profoundly relies on the presence of
other PPPSPxS motifs [28]. Here we interpret that the gap4
region, by directly regulating phosphorylation at motif E (and
possibly motif D) nearby, exerts significant effects on phosphor-
ylation of other motifs such as A and C (Figure 5) through such a
signal amplification mechanism. This may also explain why gap4
has a prominent role in the overall LRP5 and LRP6 signaling
output.
Figure 6. The context and spacing of the gap4 region together reciprocally regulate LRP5 and LRP6 signaling activities. (A and B)
Additional derivatives in the gap4 region (underlined) of *LRP5 and LRP6. The mutated residue of each derivative is in bold. Motifs D and E are boxed
and known sites phosphorylated by GSK3 (#) and CKI (*) are indicated below the alignment. The LRP6 gap4 serine is not predicted to be a CKI
phosphorylation site. (C–D) TOPFLASH reporter activity of *LRP5 and derivatives alone (C) or co-transfected with Wnt1 (D). (E–F) TOPFLASH reporter
activity of LRP6 and derivatives alone (E) or co-transfected with Wnt1 (F). The LRP6e mutant [28], which has PPPAP instead of PPPSP in motif E, was
used for comparison.
doi:10.1371/journal.pone.0023537.g006
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proteins, and is distinct from SYSH in gap4 that is invariable
among vertebrate Lrp6 orthologs (Figure S1B). Such a conserved
sequence difference together with its critical modulation of LRP5
and LRP6 signaling activity are unlikely to be co-incidental.
Although the serine and tyrosine residues in gap4 call for potential
(and differential) phosphorylation regulation in LRP5 and LRP6,
our mutational analyses do not seem to support such a scenario
(Figure 6 and data not shown). How does gap4 regulate
phosphorylation at PPPSPxS motifs and thereby LRP5/LRP6
signaling remains to be investigated. One possibility is that gap4 in
LRP5 or LRP6, perhaps in conjunction with flanking residues,
serves as a binding site for an unknown protein. Alternatively the
sequence difference between LRP5 and LRP6 results in
conformational difference that affects relative positioning of the
last two PPPSPxS motifs (D and E), impacting signal amplification.
Intriguingly the predicted secondary structure of LRP6 gap4
region contains a ‘‘turn’’ that is lacking in LRP5, and furthermore.
the LRP5+gap4S mutant gains, while the LRP6 SH.F mutant
loses, this predicted turn (Figure S3), correlating with the increase
and decrease of receptor signaling strength, respectively.
We note that while other gap regions, including gap2, do not
appear to influence LRP5/6 activities in Wnt/b-catenin signaling,
a recent study has shown that the RMTSV region of LRP6 gap2
serves as a potential phosphorylation site (T1558) for Protein
Kinase A (PKA) and mediates LRP6 and Gas interaction in
response to parathyroid hormone (PTH) binding to LRP6 [41].
This PTH responsive PKA site in gap2 is absent in Lrp5 (Figure
S1B). Although our data do not favor a similar phosphorylation-
dependent regulation of gap4, this and our studies together
highlight important regulatory roles of different gap regions
between PPPSPxS motifs in LRP5 and LRP6 in Wnt and possibly
other signaling pathways.
Our study further helps to resolve a controversial issue
regarding LRP5/6-Axin interaction. Earlier findings based on
yeast two-hybrid assays suggested that LRP5/6-Axin association is
likely direct [30] and is mediated through phosphorylated
PPPSPxS motifs as Axin-docking sites [12,13], although this
model has not ruled out the caveat that GSK3-like proteins in
yeast may have a role in mediating the two-hydrid interaction.
This direct interaction model is complicated/challenged by the
findings that GSK3 also binds to LRP6 and performs PPPSP
phosphorylation [13,34,36,37], and that phosphorylated PPPSPxS
peptides can inhibit GSK3 phosphorylation of b-catenin presum-
ably through direct interaction with GSK3 [35,36]. Furthermore
the serine/threonine-rich region upstream of the PPPSPxS motif
A (Figure S1B) may also bind to GSK3 [36,37]. Given these
scenarios and the established Axin-GSK3 interaction, a recent in
vitro study has argued that Axin-LRP6 interaction is indirect and
requires GSK3 as an intermediate bridge [36]. Using recombinant
GST-LRP5C or -LRP6C plus GSK3 (and CK1) we performed in
vitro reconstitution of phosphorylation-dependent LRP5C/
LRP6C-Axin interaction. We found that GSK3 indeed binds to
GST-LRP5C and -LRP6C, but not to control GST, this binding is
however independent of LRP5C/LRP6C phosphorylation
(Figure 4). By contrast, Axin binds only to GST-LRP5C and -
LRP6C that have been phosphorylated by GSK3 plus CK1
(Figure 4). Importantly the presence of GSK3 with LRP5C/
LRP6C does not result in Axin recruitment (Figure 4G).
Furthermore, LRP6CDS/T, which harbors a deletion of the
serine/threonine-rich region that was suggested to be a GSK3-
binding site [36,37], binds to Axin in a phosphorylation-dependent
manner that is indistinguishable to the wild type LRP6C
(Figure 4H). Therefore our results are consistent with a direct
LRP5/6-Axin interaction and do not support the model that
GSK3 is the intermediate bridge between LRP5/6 and Axin. We
note that in experiments supporting the GSK3-bridging model
[36], the authors employed an Axin fragment that lacks the so-
called DIX domain, which was suggested to be required for
LRP5/6-Axin interaction [30].
In summary we have determined that the cytoplasmic domain
of LRP5 and LRP6 plays a major role in the different signaling
activity of these two Wnt receptors, and identified between the last
two carboxyl PPPSPxS motifs an intervening gap4 region that has
a key modulatory function in LRP5/LRP6 phosphorylation and
signaling output. We have also provided evidence that argues for
direct LRP5/LRP6-Axin interaction. Collectively our data
provide significant new insights into the molecular mechanism of




Human LRP5 and LRP6 were tagged with the VSVG epitope
and cloned into pCS2+ as previously described [12]. When not
present in the endogenous sequence, unique restriction enzyme
sites were introduced using the QuickChange Mutagenesis Kit
(Stratagene). Point mutants and c-terminal insertion/deletion
mutations were created in the LRP5DN and LRP6DN constructs,
and later transferred over to the full-length receptor using the ClaI
site before the transmembrane domain. LNCX-Wnt1, LNCX-
Wnt3a or an empty LNCX vector, was used for co-expression
assays. GST-LRP5C (amino acids 1409–1615) was cloned into
pGEX4 using similar boundaries based on GST-LRP6C (amino
acids 1396–1613). GST-LRP6CDS/T contains a 14 amino acid
deletion (D1466–1479, see Figure S1B). For experiments analyzing
full-length LRP5/6 phosphorylation, pCS2-MESD was added at a
10:1 LRP5/6:MESD ratio to facilitate processing and trafficking
of the receptors to the membrane. Full details of all plasmids are
available upon request.
Dual luciferase assay
Mammalian cell transfections were done in HEK 293T cells
(ATCC# CRL-11268) using FuGENE 6 and performed in
triplicate. Cells were plated at 1610
5/ml in 24 well plates and
transfected the following day with a total of 300 ng of DNA/well
[50 ng TOPFLASH, 10 ng TK-Renilla, 90 ng pCS2+ (empty
vector), 50 ng of LNCX/Wnt1 and 100 ng of LRP5/6 constructs
or pCS2 vector control]. Dual luciferase reporter assays were
performed as previously described [28]. Representative results are
shown from one of three (or more) independent experiments.
In vitro phosphorylation and binding assays
Recombinant GSK3 (GSK3b: P6040, NEB) and CKI (CKId:
P6030, NEB) were used for in vitro phosphorylation and binding
assays as previously described [13]. Following the in vitro
phosphorylation reaction with 250 units of GSK3 and 500 units
of CKI, GST proteins were thoroughly washed to minimize the
amount of recombinant GSK3 and CKI in the future binding
assay (46 using a high salt condition: 50 mM HEPES pH 7.4,
500 mM NaCl, 1.5 mM EDTA, 1% Triton X-100, 10% glycerol).
The same HEPES buffer containing only 150 mM NaCl was used
for Axin binding conditions and post-binding washes (66).
Immunoblotting and antibodies
Polyclonal anti-VSVG (V4888, Sigma) was used to detect the
expressed LRP5/6 chimeric receptors by western blot analysis as
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mouse embryos (Lrp5 null [23] and Lrp6 null [7]). Individual cell
lines were established and immortalized using large T antigen. No
detergents were present in the lysis buffer for analysis of cytosolic
b-catenin levels (610153, BD) with b-tubulin (E7, DSHB) as a
loading control. MutliGauge analytic software (Fujifilm) was used
to calculate cytoplasmic b-catenin levels normalized to b-tubulin.
Total cell lysates were used to detect endogenous LRP5 (D80F2,
Cell Signaling) and LRP6 (C47E12, Cell Signaling) in MEFS.
GSK3 was detected using a monoclonal antibody (4G-1E,
Millipore) and Axin-Myc was detected using either a monoclonal
anti-Myc antibody (9E10, Santa Cruz) or polyclonal anti-Axin
antibody (34–5900, Invitrogen) [13]. Phospho-specific LRP6
antibodies to the A site (Ab1490, Cell Signaling), C and E sites
(Ab1572 and Ab1607, previously described [28]) were used to
verify in vitro phosphorylation of GST-LRP5C and GST-LRP6C.
Total protein was detected using SimplyBlue (Invitrogen) or
Ponceau S (Sigma).
Supporting Information
Figure S1 Location of VSVG epitope tag and alignment
of the LRP5 and LRP6 cytoplasmic domains. (A) The
predicted signal peptide cleavage site for LRP5 and LRP6.
Insertion of a VSVG epitope tag and BspEI site is a few amino acid
residues after the cleavage site. Underlined residues represent the
beginning of the first YWTD b-propeller structure. (B) ClustalW
alignment of LRP5 and LRP6 proteins from human, chicken, frog,
and zebrafish. Amino acid residues highlighted in black, grey, and
light grey represent identical, conservative, and similar amino
acids, respectively. Green boxes indicate PPPSPxS motifs A, B, C,
D and E. The conserved PstI site located after motif B in LRP5
and LRP6 cDNAs was used to create the LRP
AB/
CDE swap
constructs. The extra amino acid residues in LRP6 between the
PPPSPxS motifs compared to LRP5 in gaps 1–4 are highlighted in
yellow. Deleted residues in GST-LRP6CDS/T, D1466–1479, are
shown with asterisks. Proteins used for alignment: LRP5, Human
(NP_002326, 1407–1615), Gallus gallus (NP_001012915, 1408–
1616), Xenopus laevis (NP_001079163, 1397–1605), and Danio rerio
(NP_001170929, 1223–1430); LRP6: Human (NP_002327, 1394–
1613), Gallus gallus (XP_417286, 1349–1567), Xenopus laevis
(NP_001079233, 1394–1613), and Danio rerio (NP_001128156,
1398–1620).
(TIF)
Figure S2 Comparison of the LRP5 and LRP6 cytoplas-
mic domains using the endogenous LRP5 signal peptide.
TOPFLASH reporter activity of LRP5/6 and LRP6/5 chimeric
receptors co-transfected with Wnt1 (A) or Wnt3a (B). The dotted
line represents the activity of Wnt alone (through the endogenous
receptor).
(TIF)
Figure S3 Secondary structure prediction for LRP5 and
LRP6 cytoplamic domain containing the most carboxyl
terminal PPPSPxS motifs D and E (boxed) and the gap4
region in between (underlined). Garnier-Robson secondary
structure prediction [42] was performed via Protean from
DNASTAR Lasergene8 for full-length Human LRP5 and LRP6
using default parameters. The gap4 region of LRP6, but not
LRP5, has a predicted turn. The LRP5+gap4S mutant (more
active than LRP5) harbors a predicted turn, whereas the LRP6
SH.F mutant destroys the turn and thus resembles LRP5.
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